Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten.
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder. [Read More: Differences Between DMD and BMD?]
- Complete recruitment of the GRAND CANYON pivotal placebo-controlled cohort in the first quarter of 2025
- Seek end of Phase 2 feedback from the U.S. Food and Drug Administration (FDA) on CANYON results for sevasemten in Becker in the first half of 2025
- Report data from the Phase 2 LYNX and FOX trials in the first half of 2025 and outline potential Phase 3 plans in individuals with Duchenne
- Follow Us -
